Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 14, 2018 - Issue
Submit an article Journal homepage
49
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study

Huafang Li1 Shanghai Mental Health Centre, Shanghai Jiao Tong University School of Medicine, Shanghai, China;2 Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China
,
Yan Li1 Shanghai Mental Health Centre, Shanghai Jiao Tong University School of Medicine, Shanghai, China;2 Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China
,
Yu Feng3 Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore
,
Jianmin Zhuo4 Janssen China Research and Development, Shanghai, China
,
Ibrahim Turkoz5 Janssen Research & Development LLC, Titusville, NJ, USA
,
Maju Mathews5 Janssen Research & Development LLC, Titusville, NJ, USA
&
Wilson Tan3 Janssen Pharmaceutical Companies of Johnson and Johnson, SingaporeCorrespondence[email protected]
 show all
Pages 1107-1117 | Published online: 26 Apr 2018

Figures & data

Figure 1 Patient disposition (≤1 week versus >1 week).

Notes: Per protocol group, included all patients without a major protocol deviation; values are n (%).
Abbreviation: ITT, intent-to-treat.
Figure 1 Patient disposition (≤1 week versus >1 week).

Table 1 Demographics and baseline characteristics (ITT population)

Table 2 Distribution of time to treatment initiation

Figure 2 Difference in mean change in PANSS total score at various time points.

Notes: All values are least square means (standard error); *P≤0.05; difference between subgroups, ≤1 week minus >1 week.
Abbreviations: CI, confidence interval; PANSS, positive and negative syndrome scale.
Figure 2 Difference in mean change in PANSS total score at various time points.

Table 3 Change from baseline to each time point within subgroups

Figure 3 PANSS responder rates (.30%) at various time points.

Note: **P≤0.01 for difference in PANSS responder rates between the subgroups.
Abbreviation: PANSS, positive and negative syndrome scale.
Figure 3 PANSS responder rates (.30%) at various time points.

Table 4 Changes from baseline to week 13 in the secondary endpoints

Table 5 Categorical summary of clinical global impression-severity and personal and social performance scores

Figure 4 Summary of readiness for hospital discharge.

Figure 4 Summary of readiness for hospital discharge.

Table 6 Summary of treatment-emergent adverse events

Table S1 Institutional Review Board/Committees

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.